news

J&J reach $20.4m settlement agreement over opioid trial

3
SHARES

Johnson & Johnson have reached a settlement with two Ohio counties over its role in the opioid crisis, removing the company from the trial due to begin later this month.

Johnson & Johnson (J&J) and its Janssen Pharmaceutical Companies have announced a settlement agreement with the Ohio counties of Cuyahoga and Summit over the opioid crisis claims.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The agreement marks the fourth company to reach a settlement over the opioid crisis”

The company sold painkillers Duragesic and Nucynta, considered to have played a role in the epidemic.

A combined settlement of $10 million will be payed to the counties, which removes the company from the list of defendants at the federal trial due to begin on 21 October. However, J&J emphasises that the payment is not an admission of liability for its role in the opioid crisis.

J&J has also agreed to reimburse $5 million of the counties’ legal and other expenses incurred in preparation for the trial. A further $5.4 million will be directed towards charitable contributions to non-profit organisations related to opioid programmes in the two counties.

“The settlement allows the company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation’s opioid crisis,” J&J said in a statement.

The agreement marks the fourth company to reach a settlement over the opioid crisis ahead of trial.

Share via
Share via